novocure(NVCR) - 2024 Q2 - Quarterly Results
novocure(NVCR)2024-07-25 11:01"The second quarter was a period of consistent execution at Novocure," said Asaf Danziger, Novocure's Chief Executive Officer. "We began the year with three key objectives – grow our commercial business in glioblastoma, launch our next indication in non-small cell lung cancer, and deliver on the promise of our clinical and product development pipeline. I am pleased to share we have made significant progress on all fronts this quarter.""The second quarter was a period of consistent execution at Novocure," sa ...